Heat Biologics Inc (HTBX)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heat Biologics Inc (HTBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013953
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heat Biologics Inc (Heat Biologics) is an immuno-oncology company that develops novel therapies to activate patient’s immune system against cancer. The company develops immune pan-antigen cytotoxic therapy, which is a therapeutic vaccine used in the treatment of cancer and infectious diseases. Its pipeline products include HS-110, which is used to treat non-small cell lung cancer, and HS-410 that is used in the treatment of non-muscle invasive bladder cancer. Heat Biologics conducts multiple clinical trials in various indications. The company’s product serves various therapeutic areas such as non-small cell lung cancer, HIV infection, parasitic infections, and others. It partners with other pharma companies for its research and development activities. Heat Biologics is headquartered in Durham, North Carolina, the US.

Heat Biologics Inc (HTBX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Partnerships 15
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
Licensing Agreements 17
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Equity Offering 26
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Acquisition 36
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc – Key Competitors 37
Heat Biologics Inc – Key Employees 38
Heat Biologics Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Nov 13, 2017: Heat Biologics Reports Third-quarter 2017 Results and Corporate Update 40
May 11, 2017: Heat Biologics Provides Business and Clinical Update for the First Quarter of 2017 41
Mar 31, 2017: Heat Biologics Reports Fiscal Year 2016 Financial Results 43
Nov 10, 2016: Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 45
Aug 15, 2016: Heat Biologics Provides Corporate Update and Reports Second Quarter 2016 Financial Results 47
May 11, 2016: Heat Biologics Reports First Quarter 2016 Financial Results 49
Feb 18, 2016: Heat Biologics Reports Fiscal Year 2015 Financial Results 50
Corporate Communications 51
Oct 23, 2017: Heat Biologics and its Pelican Therapeutics Subsidiary Appoint Two New Members to their Scientific Advisory Boards 51
Jul 03, 2017: Dr. Jeff Hutchins Appointed Chief Operating Officer for Heat Biologics 52
Jan 04, 2017: Heat Biologics Appoints Jeff Hutchins, Ph.D., as Chief Scientific Officer 53
Apr 25, 2016: Heat Biologics Appoints Dr. John Prendergast to Board of Directors 54
Product News 55
Jul 07, 2016: Heat Biologics Announces “Cancer Immunology Research” Publication Featuring its ComPACT Platform Technology 55
06/28/2017: Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award 56
05/19/2016: Pelican Therapeutics awarded $15.2 million to develop novel immune therapy for multiple cancers 57
03/16/2017: Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine 58
Clinical Trials 59
Mar 07, 2016: Heat Biologics Presents Positive ComPACT Preclinical Data at the Keystone Symposia 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Heat Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heat Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heat Biologics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Heat Biologics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Heat Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Heat Biologics Raises USD0.5 Million in Venture Funding 12
Heat Biologics Raises US$5 Million In Venture Financing 13
Heat Biologics Raises US$2.83 Million In Venture Financing 14
Selexis and Pelican Therapeutics Enter into Agreement 15
Heat Biologics Enters into Agreement with Adaptive Biotechnologies 16
University of Miami Enters into Licensing Agreement with Heat Biologics 17
Shattuck Labs Enters into Licensing Agreement with Heat Biologics 18
Heat Biologics Enters into Licensing Agreement with Columbia University 19
Heat Biologics Enters into Licensing Agreement for Multiple Myeloma Cell Line 20
Heat Biologics Enters into Licensing Agreement with University of Miami 21
Heat Biologics Amends License Agreement with University of Michigan 22
Heat Biologics Enters into Licensing Agreement with American Type Culture Collection 23
Heat Biologics Enters into Four Licensing Agreements with University of Miami 24
Heat Biologics Prices USD2.5 Million of Public Offering of Shares 26
Heat Biologics Plans to Raise up to USD50 Million in Public Offering of Securities 27
Heat Biologics Prices Rights Offering of Shares for up to USD7.4 Million 28
Heat Biologics Raises USD4 Million in Public Offering of Common Stock 29
Heat Biologics Raises USD7 Million in Public Offering of Shares 30
Heat Biologics Raises USD12.3 Million in Public Offering of Shares 32
Heat Biologics Completes Underwriters’ Partial Exercise Of Over-Allotment Option For IPO Of Shares For US$27 Million 34
Heat Biologics Acquires 80% Stake in Pelican Therapeutics 36
Heat Biologics Inc, Key Competitors 37
Heat Biologics Inc, Key Employees 38
Heat Biologics Inc, Subsidiaries 39

★海外企業調査レポート[Heat Biologics Inc (HTBX)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Integrated BioPharma Inc (INBP):企業の財務・戦略的SWOT分析
    Summary Integrated BioPharma Inc (IBI) is a biopharmaceutical company that develops, manufactures and distributes vitamins, nutritional supplements and herbal products. The company’s contract business includes manufacturing, branded proprietary products, and other nutraceutical businesses. Its contr …
  • ConocoPhillips (COP):企業の財務・戦略的SWOT分析
    ConocoPhillips (COP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)-医療機器分野:企業M&A・提携分析
    Summary Jiangsu Yuyue Medical Equipment & Supply Co Ltd (Jiangsu Yuyue) is a medical device company that manufactures and distributes various medical equipments. The company’s products include electronic blood pressure monitor, air sterilization purifier, X-ray machine, blood glucose meter, temperat …
  • Swadeshi Industrial Works Plc:企業の戦略・SWOT・財務情報
    Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report Summary Swadeshi Industrial Works Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • The Vanguard Group Inc:企業の戦略的SWOT分析
    The Vanguard Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Tesaro Inc (TSRO)-医療機器分野:企業M&A・提携分析
    Summary Tesaro Inc (Tesaro) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates, comprising rolapitant, niraparib, and the product candidates under its immuno-oncology platform. VARUBI, the company’s first commercial product is …
  • RCL Foods Ltd. (RCL):企業の財務・戦略的SWOT分析
    RCL Foods Ltd. (RCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Gunvor Group Ltd:企業の戦略的SWOT分析
    Gunvor Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Qualyst Transporter Solutions LLC-医療機器分野:企業M&A・提携分析
    Summary Qualyst Transporter Solutions LLC (Qualyst Transporter Solutions), formerly Qualyst Inc is a provider of hepatic drug transporter products and contract research services using B-CLEAR technology. The company offers products such as transporter certified products, transporter interactions, he …
  • Sichuan Chuantou Energy Company Ltd (600674):電力:M&Aディール及び事業提携情報
    Summary Sichuan Chuantou Energy Company Ltd (Sichuan Investment Energy), a subsidiary of Sichuan Investment Group Co Ltd is an investment holding company. The company’s business activities include operation of hydropower stations, thermal power plant and power generation plants. It develops, constru …
  • Terumo Cardiovascular Systems Corporation:製品パイプライン分析
    Summary Terumo Cardiovascular Systems Corporation (TCSC), a subsidiary of Terumo Corporation, is a provider of medical equipment and devices for cardiac and vascular surgeries. It produces hardware products including heart-lung machines and intra-operative monitoring systems for cardiac surgeries. I …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Grand Gulf Energy Ltd (GGE):石油・ガス:M&Aディール及び事業提携情報
    Summary Grand Gulf Energy Ltd (Grand Gulf Energy), formerly Alto Energy International Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in the US oil and gas basins. It holds interests in Napoleonville Salt Dome pro …
  • EnergySolutions, Inc.:企業の戦略・SWOT・財務情報
    EnergySolutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary EnergySolutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Advanced Proteome Therapeutics Corp (APC):企業の財務・戦略的SWOT分析
    Advanced Proteome Therapeutics Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • HLL Lifecare Ltd:企業の製品パイプライン分析
    Summary HLL Lifecare Ltd (HLL) is a manufacturer of natural rubber latex condoms. The company offers products such as condoms, tubal rings, synthetic braided and coated absorbable suture, monofilament polydioxanone surgical suture, synthetic absorbable surgical suture, blood bank refrigerator, steri …
  • Sunrise Medical (US) LLC:企業の戦略的SWOT分析
    Sunrise Medical (US) LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Tenaska Inc:電力:M&Aディール及び事業提携情報
    Summary Tenaska Inc (Tenaska) is an independent power development and energy marketing company. It develops, designs, finances, and manages and operates power plants. The company purchases and sells natural gas, electric capacity, energy, and renewable energy products; acquires, manages, and optimiz …
  • Cesca Therapeutics Inc (KOOL)-医療機器分野:企業M&A・提携分析
    Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device di …
  • Maquet Holding BV & Co KG:企業の戦略的SWOT分析
    Maquet Holding BV & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆